PROPHET Study: ctDNA-Guided Personalized Induction Immunochemotherapy for NSCLC

NCT06977074 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

83

Enrollment

OTHER

Sponsor class

Conditions

Non-small Cell Lung Cancer (NSCLC)

Interventions

DRUG: PD-1 inhibitor
DRUG: Platinum Doublet

Sponsor

Sun Yat-sen University